Bacillus calmette-guerin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy

Autophagy

Volumn 6, Issue 1, 2010, Pages 46-60

  Yuk, Jae Min ^a   Shin, Dong Min ^a   Song, Kyoung Sub ^a   Lim, Kyu ^a   Kim, Ki Hye ^a   Lee, Sang Hee ^b   Kim, Jin Man ^a   Lee, Ji Sook ^a,d   Paik, Tae Hyun ^a   Kim, Jun Sang ^a,c   Jo, Eun Kyeong ^a  

^a Chungnam National University   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^c Chungnam National University College of Medicine   (South Korea)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Autophagy; BCG cell wall skeleton; JNK; Radiosensitization; Reactive oxygen species; Toll like receptor

Indexed keywords

BCG VACCINE; BENZYLOXYCARBONYL VALYLALANYLASPARTIC ACID FLUOROMETHYL KETONE; CASPASE; CASPASE INHIBITOR; CELL WALL SKELETON; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHAGY; BACTERIAL CELL WALL; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL DEATH; CELL STRAIN HCT116; COLON CANCER; CONTROLLED STUDY; CYTOSKELETON; DRUG EFFECT; HUMAN; HUMAN CELL; IN VIVO STUDY; IONIZING RADIATION; MYCOBACTERIUM BOVIS; RADIOSENSITIVITY; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; XENOGRAFT;

MYCOBACTERIUM BOVIS; MYCOBACTERIUM BOVIS BCG;

EID: 75149136162     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.6.1.10325     Document Type: Article

References (64)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Eng J Med 2004; 351:1731-40.
3. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, et al. Improving adjuvant therapy for rectal cancer by combining protractedinfusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331:502-7.
4. Minsky BD, Cohen AM, Enker WE, Saltz L, Guillem JG, Paty PB, et al. Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. Int J Radiat Oncol Biol Phys 1997; 37:289-95.
5. Kim JS, Kim JS, Cho MJ, Song KS, Yoon WH. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002; 54:403-8.
6. Freyer G, Bossard N, Romestaing P, Mornex F, Chapet O, Trillet-Lenoir V, Gérard JP. Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial. J Clin Oncol 2001; 19:2433-8.
7. Gerard JP, Chapet O, Nemoz C, Romestaing P, Mornex F, Coquard R, et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol 2003; 21:1119-24.
8. Mehta VK, Cho C, Ford JM, Jambalos C, Poen J, Koong A, et al. Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 2003; 55:132-7.
9. Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer JL, et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000; 60:1326-31.
10. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998; 394:287-91.
11. Rödel C, Arnold D, Hipp M, Liersch T, Dellas K, Iesalnieks I, et al. Phase I-II trial of cetuximab, capecitabine, oxaliplatin and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 2008; 70:1081-6.
12. Zois CE, Koukourakis MI. Radiation-induced autophagy in normal and cancer cells: towards novel cytoprotection and radio-sensitization policies? Autophagy 2009; 5:442-50.
13. Kondo Y, Kondo S. Autophagy and cancer therapy. Autophagy 2006; 2:85-90.
14. Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E, et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 2001; 61:439-44.
15. Kim KW, Mutter RW, Cao C, Albert JM, Freeman M, Hallahan DE, Lu B. Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling. J Biol Chem 2006; 281:36883-90.
16. Daido S, Yamamoto A, Fujiwara K, Sawaya R, Kondo S, Kondo Y. Inhibition of the DNA-dependent protein kinase catalytic subunit radiosensitizes malignant glioma cells by inducing autophagy. Cancer Res 2005; 65:4368-75.
17. Azuma I, Seya T. Development of immunoadjuvants for immunotherapy of cancer. Int Immunopharmacol 2001; 1:1249-59.
18. Seya T, Matsumoto M, Tsuji S, Begum NA, Azuma I, Toyoshima K. Structural-functional relationship of pathogen-associated molecular patterns: lessons from BCG cell wall skeleton and mycoplasma lipoprotein M161Ag. Microbes Infect 2002; 4:955-61.
19. Zbar B, Ribi E, Meyer T, Azuma I, Rapp HJ. Immunotherapy of cancer: regression of established intradermal tumors after intralesional injection of mycobacterial cell walls attached to oil droplets. J Natl Cancer Inst 1974; 52:1571-7.
20. Yamamura Y, Azuma I, Taniyama T, Sugimura K, Hirao F, Tokuzen R, et al. Immunotherapy of cancer with cell wall skeleton of Myocabacterium bovis-Bacillus Calmette-Guerin: experimental and clinical results. Ann N Y Acad Sci 1976; 277:209-27.
21. Yasumoto K, Manabe H, Yanagawa E, Nagano N, Ueda H, Hirota N, et al. Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guerin. Cancer Res 1979; 39:3262-7.
22. Hayashi A, Doi O, Azuma I, Toyoshima K. Immunofriendly use of BCG-cell wall skeleton remarkably improves the survival rate of various cancer patients. Proc Jpn Acad Ser B 1998; 74:50-5.
23. Murata M. Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors. Cancer Sci 2008; 99:1435-40.
24. Udagawa M, Kudo-Saito C, Hasegawa G, Yano K, Yamamoto A, Yaguchi M, et al. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation. Clin Cancer Res 2006; 12:7465-75.
25. Mizushima N. Methods for monitoring autophagy. Int J Biochem Cell Biol 2004; 36:2491-502.
26. Galluzzi L, Morselli E, Vicencio JM, Kepp O, Joza N, Tajeddine N, Kroemer G. Life, death and burial: multifaceted impact of autophagy. Biochem Soc Trans 2008; 36:786-90.
27. Blommaart EF, Krause U, Schellens JP, Vreeling-Sindelarova H, Meijer AJ. The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur J Biochem 1997; 243:240-6.
28. Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D'Amelio M, et al. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 2008; 10:676-87.
29. Xu Y, Kim SO, Li Y, Han J. Autophagy contributes to caspase-independent macrophage cell death. J Biol Chem 2006; 281:19179-87.
30. Chen Y, McMillan-Ward E, Kong J, Israels SJ, Gibson SB. Mitochondrial electron-transport-chain inhibitors of complexes I and II induce autophagic cell death mediated by reactive oxygen species. J Cell Sci 2007; 120:4155-66.
31. Majander A, Finel M, Wikstrom M. Diphenyleneiodonium inhibits reduction of iron-sulfur clusters in the mitochondrial NADH-ubiquinone oxidoreductase (Complex I). J Biol Chem 1994; 269:21037-42.
32. Tal MC, Sasai M, Lee HK, Yordy B, Shadel GS, Iwasaki A. Absence of autophagy results in reactive oxygen species-dependent amplification of RLR signaling. Proc Natl Acad Sci USA 2009; 106:2770-5.
33. Pyo JO, Nah J, Kim HJ, Lee HJ, Heo J, Lee H, Jung YK. Compensatory activation of ERK1/2 in Atg5-deficient mouse embryo fibroblasts suppresses oxidative stress-induced cell death. Autophagy 2008; 4:315-21.
34. Wei Y, Pattingre S, Sinha S, Bassik M, Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell 2008; 30:678-88.
35. Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, Hayashi A, et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infect Immun 2000; 68:6883-90.
36. Uehori J, Matsumoto M, Tsuji S, Akazawa T, Takeuchi O, Akira S, et al. Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guerin peptidoglycan. Infect Immun 2003; 71:4238-49.
37. Bhardwaj N. Harnessing the immune system to treat cancer. J Clin Invest 2007; 117:1130-6.
38. Liu CL, Chen S, Dietrich D, Hu BR. Change in autophagy after traumatic brain injury. J Cereb Blood Flow Metab 2008; 28:674-83.
39. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008; 13:472-82.
40. Codogno P, Meijer AJ. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ 2005; 2:1509-18.
41. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005; 5:726-34.
42. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer 2007; 7:961-7.
43. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Selfeating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007; 8:741-52.
44. Moretti L, Attia A, Kim KW, Lu B. Crosstalk between Bak/Bax and mTOR signaling regulates radiationinduced autophagy. Autophagy 2007; 3:142-4.
45. Kroemer G, El-Deiry WS, Golstein P, Peter ME, Vaux D, Vandenabeele P, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ 2005; 12:1463-7.
46. Golstein P, Kroemer G. Cell death by necrosis: towards a molecular definition. Trends Biochem Sci 2007; 32:37-43.
47. Tasdemir E, Galluzzi L, Maiuri MC, Criollo A, Vitale I, Hangen E, et al. Methods for assessing autophagy and autophagic cell death. Methods Mol Biol 2008; 445:29-76.
48. Yu L, Wan F, Dutta S, Welsh S, Liu Z, Freundt E, et al. Autophagic programmed cell death by selective catalase degradation. Proc Natl Acad Sci USA 2006; 103:4952-7.
49. Chen Y, McMillan-Ward E, Kong J, Israels SJ, Gibson SB. Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death Differ 2008; 15:171-82.
50. Lee SB, Bae IH, Bae YS, Um HD. Link between mitochondria and NADPH oxidase 1 isozyme for the sustained production of reactive oxygen species and cell death. J Biol Chem 2006; 281:36228-35.
51. Kissova I, Deffieu M, Samokhvalov V, Velours G, Bessoule JJ, Manon S, Camougrand N. Lipid oxidation and autophagy in yeast. Free Radic Biol Med 2006; 41:1655-61.
52. Chen Y, Gibson SB. Is mitochondrial generation of reactive oxygen species a trigger for autophagy? Autophagy 2008; 4:246-8.
53. 2-terminal kinasemediated Beclin 1 expression during anticancer agentsinduced autophagy in cancer cells. Oncogene 2009; 28:886-98.
54. Pattingre S, Bauvy C, Carpentier S, Levade T, Levine B, Codogno P. Role of JNK1-dependent Bcl-2 phosphorylation in ceramide-induced macroautophagy. J Biol Chem 2009; 284:2719-28.
55. Ventura JJ, Cogswell P, Flavell RA, Baldwin AS Jr, Davis RJ. JNK potentiates TNF-stimulated necrosis by increasing the production of cytotoxic reactive oxygen species. Genes Dev 2004; 18:2905-15.
56. Nakano H, Nakajima A, Sakon-Komazawa S, Piao JH, Xue X, Okumura K. Reactive oxygen species mediate crosstalk between NFkappaB and JNK. Cell Death Differ 2006; 13:730-7.
57. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen species promote TNFalphainduced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005; 120:649-61.
58. Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, Takeda K, et al. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep 2001; 2:222-8.
59. Kodama K, Higashiyama M, Takami K, Oda K, Okami J, Maeda J, et al. Innate immune therapy with a Bacillus Calmette-Guerin cell wall skeleton after radical surgery for non-small cell lung cancer: A case-control study. Surg Today 2009; 39:194-200.
60. Grauer OM, Molling JW, Bennink E, Toonen LW, Sutmuller RP, Nierkens S, Adema GJ. TLR ligands in the local treatment of established intracerebral murine gliomas. J Immunol 2008; 181:6720-9.
61. Azuma I, Ribi EE, Meyer TJ. Biologically active components from mycobacterial cell walls I. Isolation and composition of cell wall skeleton and component P3. J Natl Cancer Inst 1974; 52:95-101.
62. Javvadi P, Segan AT, Tuttle SW, Koumenis C. The chemopreventive agent curcumin is a potent radio-sensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol Pharmacol 2008; 73:1491-501.
63. Yang CS, Shin DM, Kim KH, Lee ZW, Lee CH, Park SG, et al. NADPH oxidase 2 interaction with TLR2 is required for efficient innate immune responses to mycobacteria via cathelicidin expression. J Immunol 2009; 182:3696-705.
64. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003; 63:4009-16.